HER2-positive Breast Cancer Video Perspectives

In a video interview, Nancy U. Lin, MD, associate chief in the Division of Breast Oncology at Susan F. Smith Center for Women's Cancers, director of the Metastatic Breast Cancer Program and director of the Program for Patients with Breast Cancer Brain Metastases at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, highlighted research and treatment advancements in HER2-positive breast cancer.

Lin discussed:

• “Practice-changing results” from DESTINY-Breast03 and the TULIP trial data presented at the virtual ESMO Congress 2021;
• Toxicity and efficacy of older vs. newer therapeutic agents for HER2-positive breast cancer;
• Current management of HER2-positive disease, which has “the goal of long-term disease control, but not really with the explicit goal of cure” and how management might look in the future – “I think we’re at the point now where we can be a little bit more ambitious in terms of our goals;”
• Why she explains that “this is a marathon, not a sprint” when positioning therapies to her patients; and
• Treatment options for patients with metastatic HER2-positve breast cancer who go beyond the second-line setting.